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Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)/
Apo1L is a death ligand, a cytokine that activates apoptosis through
cell surface death receptors. TRAIL is thought to be important in
host tumor surveillance and metastasis suppression, and various
therapeutic agonists that activate TRAIL receptors to induce tumor
cell apoptosis are in clinical development. This review discusses
recent findings about TRAIL pathway signaling and relates the
signaling mechanisms to issues that need to be considered as we try
to manipulate TRAIL signaling to treat cancer.
(J Thorac Oncol. 2007;2: 461–465)
Tumor necrosis factor-related apoptosis-inducing ligand(TRAIL, also known as Apo2L and TNFSF10) is a type
II transmembrane protein belonging to the tumor necrosis
factor (TNF) superfamily. TRAIL is expressed on the surface
of natural killer (NK) and T cells, macrophages, and dendritic
cells. As with other cytokines, the protein is synthesized in a
pro-form with a signal sequence that is removed in the mature
secreted protein. TRAIL can be anchored in the membrane
via hydrophobic amino acids or can be released as a soluble
protein. Both forms function as trimers and can induce
apoptosis. TRAIL induces apoptosis by binding to and acti-
vating signaling by trimeric death receptors in a manner that
is similar to that of other “death ligands,” such as FasL or
TNF, which signal through the Fas receptor (CD95) and
TNF receptor (TNFR1), respectively. TRAIL binds to five
different receptors. DR4 (TNFRSF10a, TRAILR1) and DR5
(TNFRSF10b, TRAILR2) are both are capable of signaling
apoptosis, whereas two membrane-bound decoy receptors
called DcR1 (TNFRSF10c) and DcR2 (TNFRSF10d) are
unable to activate apoptotic signaling and inhibit TRAIL
signaling. The fifth TRAIL-binding receptor is osteopro-
togerin (TNFRSF11b), which is a soluble protein that may
also function as a decoy/inhibitor by sequestering TRAIL
extracellularly. Much current interest in TRAIL derives from
its roles in cancer development and treatment. In particular,
recombinant TRAIL1,2 and agonistic antibodies that recog-
nize TRAIL receptors3,4 have been shown to kill many tumor
cells while leaving most normal cells unscathed and display-
ing little toxicity when delivered systemically to animals and
people. It is therefore hoped that these agents may be useful
to treat cancer.5–7 This contrasts with other death ligands,
such as TNF or Fas ligand, which activate similar pathways
using the same signaling proteins but display unacceptable
toxicity when administered systemically. In this review, I
discuss recent mechanistic insights into the TRAIL pathway,
focusing on areas that may be important as we attempt to
apply the mechanistic understanding of this signaling to
improve lung (and other cancers) cancer treatment.
FUNCTIONS OF TRAIL
The creation of TRAIL-deficient and TRAIL receptor-
deficient mice has allowed examination of the physiological
functions of TRAIL. Knockout mice are viable and fertile
with no obvious developmental defects. The TRAIL pathway
is involved in the regulation of innate immunity8 and in the
homeostasis of memory T cells.9 From the cancer perspec-
tive, TRAIL signaling is important in T cell- and natural
killer cell-mediated tumor surveillance and metastasis sup-
pression.10–13 Although TRAIL receptor deficiency has no
apparent effect on intestinal tumor development caused by
p53 or APC loss,14 TRAIL-deficient animals have more
hematological malignancies15 and are more susceptible to
chemical carcinogens.13 TRAIL receptor-deficient animals
are also less sensitive to damage caused by ionizing radia-
tion.16 Together, these findings indicate that the TRAIL
pathway has important roles in host anti-tumor defense and
tumor suppression.
MECHANISM OF TRAIL PATHWAY SIGNALING
Upon DR4 or DR5 activation by binding TRAIL or the
agonistic DR4 and DR5 antibodies, a protein complex called
the death-inducing signaling complex (DISC) is formed (Fig.
1). In the DISC, the adaptor protein FADD is bound directly
to the intracellular death domain (a protein interaction do-
main) of the receptors.17–19 FADD simultaneously binds to
the inactive pro-form of caspase-8, which is activated, prob-
ably as a result of dimer formation.20 This, in turn, leads to
activation of effector caspases that digest cellular proteins to
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cause apoptotic cell death. The stoichiometry of these inter-
actions is unclear. The TRAIL receptor functional unit is a
trimer, but it is likely that multiple trimers must be activated
together to create a functional DISC, and aggregation of
death receptors in large groups is probably required for
effective signaling. For the Fas/CD95 receptor, it has been
proposed that FADD dimers link together receptor trimers.21
Similar interactions (with the added complexity that they may
include both DR4 and DR5 receptors) likely occur for TRAIL
signaling.
Like other death receptors (particularly Fas22), two
distinct kinds of apoptosis signaling have been described, and
cells can be classified into one of two groups depending on
how they activate death receptor-induced apoptosis. Type I
cells activate large amounts of active caspase-8 in the DISC
when death receptors are activated, whereas type II cells
activate smaller amounts of caspase-8 directly and require
amplification of the apoptotic signal through the mitochon-
drial apoptosis pathway to get over the threshold of caspase
activation that is required to kill cells. The activation of this
mitochondrial amplification loop is achieved through cleav-
age of a protein called Bid, a BH3-only member of the Bcl-2
family. When cleaved by caspase-8, Bid translocates to the
mitochondria where it causes release of cytochrome c and
other apoptotic proteins.23 Differences between type I and II
cells can have important implications for tumor cell resis-
tance mechanisms that could limit the effectiveness of
TRAIL-targeted therapies. For example, Bcl-2 over-expres-
sion would not provide a viable resistance mechanism in a
type I tumor cell, whereas it would confer TRAIL resistance
in the type II cell. It is too early to say whether such
mechanisms will arise in people being treated with the new
TRAIL receptor-targeted therapies; however, these consider-
ations underscore how rational treatment strategies might be
adopted—e.g., one could imagine that combining a Bcl-2
family inhibitor with TRAIL might be useful in treating
patients whose tumor cells are type II, but this combination
might not be helpful for a patient with type I tumor cells.
Other signaling pathways leading to NFB activation and
activation of the ERK, JNK, and p38 MAP kinase pathways are
induced by TRAIL receptors. Some of these signals (NFB,
JNK, and p38) are generated by a second cytoplasmic complex
that forms after the DISC.24 The mechanism of ERK activation
is currently unclear. The importance of these pathways is shown
by studies in cells that are resistant to the apoptotic signaling.
In such cells, TRAIL receptor stimulation can lead to in-
creased tumor cell growth and survival25,26 through the acti-
vation of NFB by the TRAIL receptors. Similar pro-tumor-
igenic effects of death receptor activation have also been
noted for the Fas/CD95 receptor.27,28 Other pro-tumorigenic
mechanisms of TRAIL receptor signaling have also been
noted. For example, TRAIL stimulation of pro-inflammatory
cytokines has been linked to increased metastasis in a pan-
creatic cancer model.29 An important conclusion arising from
these studies is that, as we try to activate TRAIL receptor
signaling for cancer therapy (see “TRAIL Signaling and Cancer
Therapy”), we should try to minimize the ability of the TRAIL
receptor agonists to activate these various pro-tumorigenic sig-
naling events.
DISC formation leading to effective signaling was
originally thought to occur randomly at the cell surface.
However, it is now apparent that localization of these signal-
ing complexes in particular regions of the membrane may be
critical for the efficiency of signaling and may even lead to
different cellular responses being mediated by the same
signaling proteins. For example, the interaction among
caspase-8, FADD, and receptors may occur on lipid rafts.
Lipid rafts are specialized cholesterol-rich domains in the cell
membrane that promote preferential concentration of partic-
ular signaling proteins to provide distinct signaling activities.
Signaling from lipid rafts is often different from that achieved
by the same signaling proteins in different subcellular loca-
tions. For example, lipid rafts differentially affect NFB30
and ERK31 signaling by the death receptor TNFR1. Recent
work indicates that redistribution of DR4 and DR5 into
rafts may explain the anti-tumor effects of other
agents,32,33 suggesting that lipid raft association of TRAIL
receptors may be an important aspect of their regulation. In
addition, COX2 inhibition sensitizes to TRAIL-induced
apoptosis by promoting DR5 clustering in cholesterol- and
ceramide-rich caveolae.34
Death receptors also signal from other sites in the cell
in addition to the plasma membrane. For example, some
signaling by TNFR1 and Fas death receptors occurs within
vesicles in the cytoplasm after receptor endocytosis.35,36 We
know much less about the role of spatial organization in
controlling TRAIL pathway signaling. However, given the
marked similarities in signaling mechanisms between Fas/
CD95 and DR4 and DR5 and the evidence that formation of
cytoplasmic complexes after TRAIL receptor stimulation is
important for activation of the non-apoptotic pathways,24 it
FIGURE 1. Binding of tumor necrosis factor-related
apoptosis-inducing ligand (TRAIL) or agonistic antibodies to
the TRAIL receptors promotes recruitment of the adaptor
protein FADD, which recruits pro-caspase-8. Dimerization of
caspase-8 leads to its activation. In type I cells, this provides
sufficient caspase activity to digest and activate effector
caspases that induce apoptosis. In type II cells, the BH3 pro-
tein Bid is cleaved to activate the mitochondrial apoptosis
pathway and thus activate effector caspases. A second com-
plex in the cytoplasm activates other signaling pathways,
including JNK and NFB.
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seems likely that similar spatial regulation will also be found
to be important for TRAIL signaling.
INHIBITION OF TRAIL SIGNALING
There are several ways to inhibit the TRAIL pathway.
Many of these mechanisms are found in tumor cells and
contribute to decreased sensitivity to TRAIL-induced apopto-
sis. These mechanisms could therefore limit the efficacy of
TRAIL receptor-targeted therapeutics and inhibit host tumor
surveillance and metastasis suppression. As mentioned in
“Mechanism of TRAIL Pathway Signaling,” two non-signal-
ing receptors (DcR1 and DcR2) are expressed in mammalian
cells along with DR4 and DR5. It was thought that these
receptors, which lack all or most of the intracellular death
domain, act as simple decoys by competing with DR4 and
DR5 for ligand binding. However, recent work37,38 suggests
that DcR1 and DcR2 inhibit signaling by different mecha-
nisms; DcR1 works by titrating away the ligand, whereas
DcR2-mediated inhibition involves the formation of heterol-
ogous complexes with DR5. In some cases, increased expres-
sion of these decoy receptors has been correlated with TRAIL
resistance in tumor cells.
DR4 and DR5 map to chromosome 8p21–22, a site of
frequent allelic loss in tumors. This led to the suggestion that,
as potential tumor suppressors, TRAIL receptors may also
harbor somatic mutations. Several studies identified somatic
mutations in gastric,39 non-Hodgkin’s lymphoma,40 non-
small cell lung,41,42 and breast43 cancers. Mutations were
fairly common, arising in 7 of 57 breast cancers (12%; 20%
of patients with lymph node involvement),43 11 of 104 lung
cancers (11%),41 and 3 of 47 gastric cancers (6.5%).39 Most
mutations are in DR5 and affect the intracellular domain of
the receptor; i.e., the region that binds FADD. Despite the
small numbers of patients studied, some mutations have been
found repeatedly in different tumor types and among different
patients with the same disease, suggesting that DR4/DR5
mutations may have important functional effects among pa-
tients with cancer.
Other mechanisms that inhibit TRAIL signaling in-
clude increased expression of inhibitors such as FLIP.44–47
FLIP is a homolog of caspase-8 with mutations in the cata-
lytic domain that prevent its activation as a protease. FLIP
expression is controlled by other important oncogenic path-
ways. For example, Myc regulation of TRAIL sensitivity may
be largely mediated through Myc’s ability to repress FLIP
expression.48 When recruited to the activated receptor com-
plex, FLIP can inhibit activation of caspase-8 and thus block
downstream apoptosis signaling. However, the reality is ac-
tually more complicated because FLIP comes in two iso-
forms, and low levels of the longer isoform may actually
stimulate caspase-8 activation or alter its substrate specificity
when death receptors are activated.49,50 Other, more general
apoptosis inhibitors (e.g., IAP proteins that interfere with
caspase activation), can also inhibit TRAIL signaling and
may limit the effectiveness of tumor cell killing by TRAIL
when over-expressed.
TRAIL SIGNALING AND CANCER THERAPY
Notwithstanding these caveats about the pro-tumori-
genic effects of TRAIL pathway activation, most of the
current interest in TRAIL pathway as it relates to cancer
focuses on plans to directly activate TRAIL receptors as a
way to kill tumor cells. These ideas arise from early indica-
tions that there was preferential TRAIL receptor-dependent
killing of tumor cells compared with normal cells, with the
result that TRAIL and agonistic antibodies that activate DR4
or DR5 have become attractive candidates as cancer thera-
peutics.7,51,52 The first phase I trials of TRAIL receptor
agonistic antibodies were reported at the 2004 ASCO meet-
ing. It is encouraging that these agents do not display sys-
temic toxicity in humans,53,54 and several clinical trials are
ongoing at multiple sites worldwide. In preclinical testing,
these agents can be highly effective in reducing tumor growth
as single agents. For example, in an orthotopic lung cancer
model, treatment with recombinant TRAIL caused 60% re-
duction in tumor growth55 and HGS-ETR1 (mapatumumab),
a human DR4 monoclonal antibody has been shown to induce
cell death and tumor regression in multiple tumor types,
including lung, colon, and renal tumors.56 It is unclear
whether recombinant TRAIL or the agonistic antibodies will
be more effective drugs. TRAIL requires careful manufacture
to correctly coordinate an essential zinc atom that is required
for proper structure and has a shorter half-life than the
antibodies; therefore, one might believe that the antibodies
would be more effective than the ligand. However, because
the antibodies activate either DR4 or DR5 but do not affect
the other receptor, whereas TRAIL activates both DR4 and
DR5, optimal clinical use of these agents may require selec-
tion based on the specific characteristics of the tumor. For
example, a patient whose tumor has a mutant version of DR5
but wild-type DR4 may obtain no benefit from treatment with
anti-DR5 but might benefit from anti-DR4 or TRAIL. Simi-
larly, at least in some tumor types, efficient apoptosis signal-
ing may occur through only one of the receptors even when
the other receptor is present and not mutated.57
Conventional chemotherapy agents and ionizing radia-
tion can synergize with TRAIL receptor agonists.58,59 For
example, paclitaxel, other tubulin-targeted drugs, radiation,
and DNA-damaging chemotherapy synergize with
TRAIL.60–62 Thus, it is hoped that combining TRAIL or
agonistic TRAIL receptor antibodies with chemotherapy or
radiation may be more effective than either treatment alone.
For example, in the lung cancer study described above,
combining TRAIL with taxol plus carboplatin led to a 97%
reduction in tumor growth.55 It may also be beneficial to
combine TRAIL with agonistic antibodies that activate T
cells.63
TRAIL receptor signaling may also be an important
determinant of the therapeutic response with other agents
(i.e., when exogenous TRAIL or the agonistic antibodies are
not part of the treatment). Direct evidence for such an effect
comes from the finding that inducible silencing of DR5 leads
to acquired resistance to 5-fluorouricil.64 In addition, in-
creased expression of DcR2 can regulate sensitivity to DNA
damaging chemotherapy.65 Anti-tumor effects of chemother-
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apy and synergy between TRAIL and other chemotherapy
drugs or radiation may be mediated by alterations in the
subcellular location32,33 or increased expression of the
TRAIL receptors.59 However, the simple view frequently
found in the literature that other agents increase TRAIL
receptors and that this is the source of the synergy may be
incorrect.66 More complicated synergy mechanisms may, in
fact, apply. Thus, in addition to the direct use of TRAIL
receptor agonists as anti-cancer therapeutics, alterations in
TRAIL receptor signaling may affect response to other ther-
apies.
SUMMARY
Although the TRAIL pathway may seem like a rather
simple apoptosis signaling pathway (the receptors bind the
ligand and then directly activate caspases), it is, in fact, quite
complicated. We have two receptors that may not function
equivalently and that can induce both pro-apoptotic and
pro-survival/growth signaling. Somatic mutations in tumor
cells can affect one or other of the TRAIL receptors while
leaving the other untouched. We have two membrane-bound
decoy receptors that work in subtly different ways and nu-
merous other inhibitors such as FLIP, which themselves may
have different effects in different contexts. Spatial regulation
of signaling complex formation (in different regions of the
cell membrane, such as lipid rafts and inside the cell) can
differentially regulate the signaling that is obtained. All of
these effects may be influenced by other treatments such as
DNA damaging chemotherapy and ionizing radiation. It is
inherently attractive to manipulate these pathways in cancer
treatment because we are trying to boost signaling through
pathways that are probably an important aspect of normal
host defenses against tumor development and metastasis.
Moreover, a number of different agents (antibodies and the
recombinant ligand) are now being tested in the clinic to do
just this. By better understanding how the signaling works
and making sense of the complexity, we will hopefully be
able to maximize the benefit to be obtained from these agents.
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